Metabolic syndrome is more prevalent in PsA than in psoriasis and RA

Key clinical point: The prevalence of metabolic syndrome (MetS) was significantly higher in patients with psoriatic arthritis (PsA) than those with psoriasis or rheumatoid arthritis (RA).

Major finding: Patients with PsA were 1.61 (95% confidence interval [CI], 1.49-1.74) and 1.66 (95% CI, 1.54-1.79) times more likely to have MetS than patients with psoriasis and RA, respectively.

Study details: Findings are from a systematic review and meta-analysis of 24, 89, and 53 studies on PsA, psoriasis, and RA, respectively.

Disclosures: The study reported no source of funding and conflicts of interest.

Source: Loganathan A et al. Int J Rheum Dis. 2021 Jun 2. doi: 10.1111/1   756-185X.14147.

Key clinical point: The prevalence of metabolic syndrome (MetS) was significantly higher in patients with psoriatic arthritis (PsA) than those with psoriasis or rheumatoid arthritis (RA).

Major finding: Patients with PsA were 1.61 (95% confidence interval [CI], 1.49-1.74) and 1.66 (95% CI, 1.54-1.79) times more likely to have MetS than patients with psoriasis and RA, respectively.

Study details: Findings are from a systematic review and meta-analysis of 24, 89, and 53 studies on PsA, psoriasis, and RA, respectively.

Disclosures: The study reported no source of funding and conflicts of interest.

Source: Loganathan A et al. Int J Rheum Dis. 2021 Jun 2. doi: 10.1111/1   756-185X.14147.

Key clinical point: The prevalence of metabolic syndrome (MetS) was significantly higher in patients with psoriatic arthritis (PsA) than those with psoriasis or rheumatoid arthritis (RA).

Major finding: Patients with PsA were 1.61 (95% confidence interval [CI], 1.49-1.74) and 1.66 (95% CI, 1.54-1.79) times more likely to have MetS than patients with psoriasis and RA, respectively.

Study details: Findings are from a systematic review and meta-analysis of 24, 89, and 53 studies on PsA, psoriasis, and RA, respectively.

Disclosures: The study reported no source of funding and conflicts of interest.

Source: Loganathan A et al. Int J Rheum Dis. 2021 Jun 2. doi: 10.1111/1   756-185X.14147.